

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



BI-847325

Purity:

Item No. 18301

CAS Registry No.: 1207293-36-4

Formal Name: 3-[3-[[[4-[(dimethylamino)methyl]

> phenyllaminolphenylmethylenel-2,3-dihydro-2-oxo-1H-indol-6-yl]-

N-ethyl-2-propynamide

MF: $C_{29}H_{28}N_4O_2$ FW: 464.6

UV/Vis.: λ_{max} : 298, 398 nm A crystalline solid Supplied as:

>98%

-20°C Storage:

Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when

stored properly

Laboratory Procedures

BI-847325 is supplied as a crystalline solid. A stock solution may be made by dissolving the BI-847325 in the solvent of choice. BI-847325 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of BI-847325 in these solvents is approximately 0.3, 5, and 16 mg/ml, respectively.

BI-847325 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BI-847325 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. BI-847325 has a solubility of approximately 0.14 mg/ml in a 1:6 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

BI-847325 is a selective dual MEK/Aurora kinase inhibitor with IC₅₀ values of 3, 25, 15, 25, and 4 nM for X. laevis Aurora B, human Aurora A and Aurora C, and human MEK1 and MEK2, respectively. It can inhibit the growth and survival of both treatment-naive and drug-resistant melanoma cell lines, decreasing the expression of MEK and McI-1 while increasing the expression of pro-apoptotic protein Bim. 1 At 70 mg/kg, BI-847325 induces apoptosis in treatment-naive and drug-resistant xenografted melanoma in vivo. 1

Reference

1. Phadke, M.S., Sini, P., and Smalley, K.S.M. The novel ATP-competitive MEK/aurora kinase inhibitor BI-847325 overcomes acquired BRAF inhibitor resistance through suppression of Mcl-1 and MEK expression. Mol. Cancer Ther. 14(6), 1354-1364 (2015).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/10/2016

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM